Related Experiment Videos
Isolation and characterization of HPRT-deficient human hepatoma cells
1Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98104, USA.
Abstract:
Human hepatoma cells deficient in HPRT activity were isolated by challenging HepG2 cells with 6-thioguanine (6TG). Three 6TG-resistant isolates were plated in selective media, and each clonal line displayed an 8-azaguanine-resistant, HAT-sensitive phenotype. The HPRT-deficient phenotype of one of these clones, H30-1, was confirmed in genetic tests: the HAT-sensitivity of H30-1 cells was complemented by fusion by HPRT+ (Ltk-) but not HPRT- (A9) cells. Furthermore, transfection of the bacterial xanthine-guanine phosphoribosyl transferase (gpt) gene into H30-1 cells rendered them HAT-resistant. H30-1 cells maintained the differentiated morphology, growth characteristics, fusion properties, and transfection efficiencies typical of parental HepG2 cells, and they expressed several liver-specific genes. Finally, the H30-1 cell line contained a modal number of 50 chromosomes. Therefore, H30-1 cells represent an HPRT-deficient HepG2 derivative that retains its differentiated phenotype in vitro.
Insights
Researchers developed HPRT-deficient HepG2 cells, named H30-1, for studying liver cancer. These cells retain key liver cell characteristics, making them valuable tools for in vitro research.
Area of Science:
- Biochemistry
- Cell Biology
- Genetics
Background:
- Hypoxanthine-guanine phosphoribosyl transferase (HPRT) is crucial for purine salvage pathways.
- HPRT deficiency leads to Lesch-Nyhan syndrome and drug resistance.
- HepG2 cells are a widely used human hepatoma cell line for liver research.
Purpose of the Study:
- To isolate and characterize human hepatoma cells (HepG2) deficient in HPRT activity.
- To confirm the retention of differentiated characteristics in HPRT-deficient HepG2 cells.
- To establish a valuable cell line for in vitro studies involving drug resistance and gene expression.
Main Methods:
- HepG2 cells were challenged with 6-thioguanine (6TG) to select for resistant clones.
- Phenotypic analysis included 8-azaguanine resistance and HAT sensitivity.
- Genetic confirmation involved cell fusion complementation assays and gene transfection with the bacterial gpt gene.
Main Results:
- Three 6TG-resistant clonal lines were isolated, all exhibiting an 8-azaguanine-resistant, HAT-sensitive phenotype.
- The H30-1 clone confirmed HPRT deficiency, showing complementation with HPRT+ cells and HAT resistance after gpt gene transfection.
- H30-1 cells maintained HepG2's differentiated morphology, growth, fusion properties, transfection efficiency, and expression of liver-specific genes.
Conclusions:
- The H30-1 cell line is a derivative of HepG2 cells lacking HPRT activity.
- H30-1 cells retain their differentiated phenotype, making them suitable for in vitro research.
- This HPRT-deficient cell line offers a valuable model for studying purine metabolism and drug resistance in liver cancer.